Avid Bioservices Inc (CDMO)

[entdoc]

thealias2002, instead it looks as if this p3 was another similar p2? The trial design apparently assumed equality between groups. If there was, in fact, equality between the two patient cohorts, the control arm and the treatment arm, then Bavi apparently does not have significant effect on advanced lung cancer. But that remains to be seen because the Bavi-chemo treated cohort performed up to expectation, or appeared to be extending life beyond the average time that would be expected with chemotherapy alone. There are some things a trial design just cannot work around. If an athletic trial among two cohorts of first graders assumes equality, and most of one group are born in the first quarter of the year, and most of the other group are much younger, born in the last quarter, then that age difference would have a profound effect on athletic coordination. So you can imagine the control group will be of great interest to Garnick and others who designed this study, but when the control group differences are ferreted out it will be too late. Most end-stage cancer patients have been treated with multiple medications, and I believe one qualification for entrance into this study was that entrants have untreated advanced lung cancer. I could be wrong on that one.